| Previous close | 1.2600 |
| Open | 1.2000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 90.00 |
| Expiry date | 2023-07-21 |
| Day's range | 1.1200 - 1.3100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Motley Fool
This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now
The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment. The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline. As a result, Moderna could launch other potential blockbusters over the next few years.
- Zacks
Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
- Zacks
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
© 2023 Yahoo. All rights reserved.
